Latest News
Palatine-backed Verdant Leisure has bought two premium leisure parks in County Durham for an undisclosed sum from Park Leisure Holiday Homes.
The acquisition of Kingfisher and Heather View holiday parks in the Wear Valley brings the boutique leisure park operator’s portfolio to six sites across southern Scotland and North East England.
The acquisition supports the board’s growth strategy to create a regional group with significant scale and is the firm’s first purchase since Palatine Private Equity backed a secondary buyout of Verdant Leisure from RJD Partners in April this year.
Set in 23 acres on the banks
- 23/06/2016
Private equity firm Wynnchurch Capital has appointed Chris Curfman to its Executive Advisory Board.
Curfman was most recently President of Caterpillar Global Mining and Senior Vice President of CAT Inc.(NYSE:CAT), the world's leading manufacturer of construction and mining equipment.
Curfman's career with Caterpillar Global Mining and CAT Inc. spans over 21 years and includes leadership roles in the Asia-Pacific division and Australia. As President of Global Mining, he led the single largest business unit within the company for over ten years. Curfman had a 15-year career at Deere & Company, ultimately serving as President/General Manager of Equipment Remarketing Services.
Curfman
- 23/06/2016
Pearl Capital Business Funding, a provider of direct financing to small and midsize businesses, has closed on a USD20 million financing from Arena Investors, a New York-based global investment firm.
"With the support of our outstanding financial partners we can continue to expand our mission of supplying funding to any small business with the desire for capital and ability to thrive," says Solomon Lax, Chief Executive Officer, Pearl Capital Business Funding. "We understand that despite personal credit issues, many small business owners have triumphed in building successful businesses. Locked out of the traditional bank financing channels, those small business owners
- 23/06/2016
Biopharmaceutical company IFM Therapeutics has closed a USD27 million Series A financing led by Atlas Venture and Abingworth, with participation from Novartis.
In conjunction with the funding Jean-François Formela and Vincent Miles, Partners at Atlas and Abingworth respectively, have joined IFM’s CEO, Gary D. Glick, on the board of directors, with Dr. Formela serving as chair of the board.
IFM Therapeutics raises USD27M Series A to develop novel immune modulators for cancer and inflammatory diseases
IFM Therapeutics, incubated as a part of the Atlas Venture seed program, is developing modulators of novel targets that either enhance innate immune responses for
- 23/06/2016
BlackFin Capital Partners is launching a new venture fund, focusing on FinTech opportunities across Europe.
After successfully launching 2 generations of growth-equity financial services funds (Fund I: EUR220 million raised in 2011/Fund II: EUR400 million raised in 2016), BlackFin Capital Partners is leveraging its unique expertise in the venture capital segment.
The fund will partner with entrepreneurs at all investment stages, from seed to late-stage rounds. As a sector specialist firm, BlackFin and its team will provide these entrepreneurs with unique support regarding their strategy and growth, commercial access and credibility, but also regulatory guidance to establish best-of-breed companies. The
- 23/06/2016
Invest Europe has appointed Dr Gerry Murphy, Senior Managing Director and Chairman of Blackstone Europe, as Chair of the Association. He succeeds Max Römer, Founding Partner of Quadriga Capital.
Murphy has been a senior figure in Blackstone’s team in London since joining the US alternative investments manager in 2008. His primary focus is on supporting the firm’s activities across Europe and Asia. He serves as a director of German clothing group Jack Wolfskin, Dutch administrative services firm Intertrust and British television and internet retailer Ideal Shopping Direct. He is also a non-executive director of British American Tobacco.
Murphy says:
- 23/06/2016
- 23/06/2016
Blackstone Strategic Capital Holdings Fund (BSCH), a vehicle managed by Blackstone Alternative Asset Management (BAAM), has acquired a passive, minority interest in Marathon Asset Management.
Based in New York, Marathon is an opportunistic global credit event-driven manager with approximately USD12.75 billion in assets under management. The firm pursues credit through a broad spectrum of investments in global corporate credit, distressed and special situational credit, structured credit, emerging markets and leveraged loans.
“Rich has been a great Partner for many years and we wish him success in his future endeavours. Vijay and I have worked together for nine years and I
- 23/06/2016
PwC's new Global 100 Software Leaders ranking illustrates a rapidly shifting landscape and reveals three key trends among companies that are taking advantage of both evolutionary and revolutionary changes in the software industry.
Within this shifting environment, the interwoven trends of digital innovation, Industry 4.0 and convergence are driving opportunities to create smarter, leaner and better software. As these trends fuel the industry, we're seeing an increasing number of startups coming to the forefront, adding to the challenges facing legacy software vendors and their customers.
The three key themes weigh heavily on PwC's overarching research findings:
• The software industry
- 23/06/2016
Livingstone’s Business Services and Debt Advisory teams have advised The Gap Partnership Group (TGP) on securing a one-stop funding solution from Pricoa Capital Group.
Founded in 1997, TGP is recognised internationally as the leading provider of negotiation behavioural change development programmes and client-specific negotiation consulting services. TGP has a global presence served by four regional hubs in the UK, USA, Germany and Hong Kong, working with over 500 of the world's largest blue-chip corporations.
The funding package from Pricoa has provided shareholder liquidity, whilst also enabling an ownership transition, putting greater ownership in the hands of the extended leadership
- 23/06/2016
IFM Therapeutics, a biopharmaceutical company developing a portfolio of small molecules targeting the innate immune system, has closed a USD27 million Series A financing led by Atlas Venture and Abingworth, with participation from Novartis.
In conjunction with the funding Jean-François Formela and Vincent Miles, Partners at Atlas and Abingworth respectively, have joined IFM’s CEO, Gary D Glick, on the board of directors, with Dr Formela serving as chair of the board.
IFM Therapeutics, incubated as a part of the Atlas Venture seed program, is developing modulators of novel targets that either enhance innate immune responses for treating cancer, or dampen
- 23/06/2016
Special Reports
Featured
- Intel
- May 17, 2024
- Awards
- May 16, 2024
- Intel
- May 16, 2024
- Intel
- May 15, 2024
- Intel
- May 13, 2024
Events
05 June, 2024 – 8:30 am
12 September, 2024 – 8:30 am
12 September, 2024 – 6:00 pm
24 October, 2024 – 8:30 am
